diagnost tool
second consecut miss challeng thesi look
analyst day clariti
quest deliv second consecut miss time top line came
us big pictur form darker cloud prior updat given
recent uptick patient concess self-pay patient contribut out-of-pocket
deduct etc expect reduct rate move in-network
total impact flip side confid
add revenu growth growth
unspecifi lift grow retail footprint safeway risk/
reward seem balanc believ buy thesi challeng
await greater clariti setup updat lt target ahead
novemb analyst day lower pt reduc
adj ep
miss rev miss street
miss revenue /req miss estim vs
adj ep y/i match street beat cite
linger impact seen form headwind prescript drug monitor
hepat genotyp vitamin test howev start
moder lap bigger concern higher mix patient concess
american respons pay higher out-of-pocket deduct think rise
patient deduct grow partli underappreci concern us healthcar
volum volum grew organ volum
grew weather hurrican florenc neg impact
indic slight neg impact think less
guide/model lower revenue guid y/i
y/i tighten adj ep guid
lower rev lower revenue
growth lower adj ep
adj ep
aet contract reach physician unit network
use lh in-network lab alreadi win new custom
small benefit believ number account
use anoth lab in-network big opportun
take share comment much benefit expect captur
estim add rev first two year
year expect volum shift unh/aet take time play beyond
 announc deal medxm cap cod hospit
provant hurley medic center hospit outreach complet
acquisit ad point revenue growth contribut
volum expect drive point revenu growth
 longer term run-rat basi think manag may updat increas
target upcom analyst day schedul novemb new york
price close busi octob
largest clinic lab us
focus routin gene-bas esoter test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
recap recent deal busi
sale india medic dx busi strand life scienc
 lab servic oxford immunotec specialti region lab expect close
deal
what bake guidanc
hcv genotyp resist test expect return growth
prescript drug monitoring- plan place revers number polici
chang serv off-set denial seen
vitamin testing- believ misunderstand around appropri
code vitamin test expect mitig throughout back half
profession lab servic pl agreements- expect close agreement
yet announc
buy unchang target price octob
diagnost tool
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price octob
diagnost tool
canaccord genuiti estim compani report
buy unchang target price octob
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin octob et
date time product octob et
price target appli multipl adj ep estim assum view modest
earn growth project believ potenti faster top-lin growth contribut accret capit
deploy would mark upsid adj ep estim
laboratori corpor america hold lh
price target lh appli multipl adj ep estim assum view
modest earn per share growth project believ potenti faster top-lin growth contribut
accret capit deploy would mark upsid adj ep estim
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
buy unchang target price octob
diagnost tool
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
